Ionis Pharmaceuticals宣布,其药物Olezarsen在治疗严重高甘油三酯血症患者的关键3期Core和Core2研究中取得积极的顶线结果。这一研究成果为该公司在代谢性疾病治疗领域的发展提供了重要支撑。
Ionis Pharmaceuticals宣布,其药物Olezarsen在治疗严重高甘油三酯血症患者的关键3期Core和Core2研究中取得积极的顶线结果。这一研究成果为该公司在代谢性疾病治疗领域的发展提供了重要支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.